Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China.

ABSTRACT:

Background

All-oral regimens are associated with higher effectiveness and shorter treatment duration for chronic hepatitis C. Given its superior effect and enormous patients in China, clinicians or patients may be compelled to consider delaying treatment for all-oral regimen.

Objective

To estimate cost-effectiveness of delaying treatment for all-oral regimen in the subsequent years under different assumptions about their price and efficacy compared with standard of care in China.

Methods

A state-transition Markov model was developed to estimate lifetime costs and quality-adjusted life years (QALYs). Incremental cost-effectiveness ratio (ICER) and net monetary benefit (NB) were calculated. And sensitivity analyses were also performed to assess the impact of uncertainty

SUBMITTER: Chen H 

PROVIDER: S-EPMC5381915 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature